REG4 Antibody

Code CSB-PA267290
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using CSB-PA267290(REG4 Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: ×200)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
REG4
Alternative Names
Gastrointestinal secretory protein antibody; GISP antibody; Reg IV antibody; REG like protein antibody; REG-4 antibody; REG-like protein antibody; Reg4 antibody; REG4_HUMAN antibody; Regenerating gene type IV antibody; Regenerating islet derived family member 4 antibody; Regenerating islet derived protein 4 precursor antibody; Regenerating islet-derived protein 4 antibody; Regenerating islet-derived protein IV antibody; REGIV antibody; RELP antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Fusion protein of Human REG4
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:2000
IHC 1:10-1:50
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Calcium-independent lectin displaying mannose-binding specificity and able to maintain carbohydrate recognition activity in an acidic environment. May be involved in inflammatory and metaplastic responses of the gastrointestinal epithelium.
Gene References into Functions
  1. Our study demonstrated that Reg IV positively regulates the expression of SOX9 and is involved in tumor cell invasion and migration in gastric cancer. PMID: 29587675
  2. Reg4 inhibited apoptosis through regulating MAPK/Erk/Bim signaling pathway and thereby enhanced the resistance of gastric cancer to 5-Fluorouracil. PMID: 28759561
  3. Data indicate that REG4 tissue expression is a prognostic marker in subgroups of pancreatic ductal adenocarcinoma patients, and Serum REG4 level might be useful in differential diagnosis between pancreatic ductal adenocarcinoma and chronic pancreatitis. PMID: 29542402
  4. REG4 promotes peritoneal metastasis of gastric cancer through GPR37 and triggers a positive feedback loop. PMID: 27036049
  5. Study demonstrated that REG4, which is overexpressed in pancreatic ductal adenocarcinoma and secreted by cancer cells, promoted macrophage polarization to M2, through at least in part, activation of ERK1/2 and CREB. PMID: 26531138
  6. REG4 is a transcriptional target of GATA6 and is essential for colorectal tumorigenesis. PMID: 26387746
  7. This study identifies REG4 as a potential serum biomarker for histotype-specific detection of mucinous ovarian cancer and suggests serum REG4 measurement as a non-invasive diagnostic tool for follow-up of patients with mucinous ovarian cancer. PMID: 26981633
  8. aberrant REG4 expression plays an essential role in early ovarian carcinogenesis and is closely linked to mucinous ovarian tumors, differentiation and adverse prognosis of ovarian cancer by modulating proliferation, apoptosis, migration and invasion. PMID: 26077911
  9. REG4 expression associated with favorable clinicopathological parameters and with higher overall survival from non-mucinous PMID: 25295732
  10. The Reg IV may be involved in the finetuning of functions exerted by the neuroendocrine cells in the GI-tract. PMID: 23499801
  11. Colorectal tumor patients with Reg4- and MMP-7-positive tumors had extremely poor overall survival. PMID: 25338725
  12. High expression of REG4 is associated with poor therapeutic response, adverse outcome and an aggressive phenotype in rectal cancer patients treated with neoadjuvant chemoradiotherapy. PMID: 25155043
  13. miR-24 functions as a novel tumor suppressor in gastric cancer, and the anti-oncogenic activity may involve its inhibition of the target gene REG4. PMID: 24886316
  14. REG4 expression is common in mucinous borderline ovarian tumors of the intestinal type as it is absent in the endocervical-like form tumors. PMID: 23958547
  15. the combination of VEGF-C and Reg IV may be a promising factor for clinical staging to supplement the classical TNM classification system. PMID: 24101199
  16. the stemness properties of control mammospheres and RegIV knockdown mammospheres were compared by tumourigenicity assay in vivo and plate colony formation assay in vitro. PMID: 24064664
  17. Reg4-induced mitogenesis involves Akt-GSK3beta-beta-Catenin-TCF-4 signaling in human colorectal cancer. PMID: 24151146
  18. Immunohistochemistry against known cell-type markers on serial sections has localised the expression of REGs to metaplastic Paneth cells (REG1A, REG1B and REG3A) and enteroendocrine cells (REG4), with a marked expansion of expression during inflammation. PMID: 23519454
  19. CDX2 protein directly regulates Reg IV expression in gastric cancer PMID: 23133598
  20. RegIV may play an important role in the intrinsic resistance of gastric cancer cells to 5-FU. PMID: 23010741
  21. Suggest that Reg IV might accelerate disease progression and act as a candidate prognostic marker for gliomas. PMID: 22713481
  22. REG4 promotes not only growth but also in vitro invasiveness of pancreatic cancer cells by upregulating MMP-7 and MMP-9. PMID: 22957785
  23. TGF-beta signalling reduces the expression of ALDH1 and REG4, and the size of the ALDH1+ cell population. PMID: 22430847
  24. Knockdown of Reg IV impacted the ability of insulin and EGF to stimulate downstream tyrosine phosphorylation. PMID: 21445968
  25. REG4, BIRC5 and NEIL2 genes might have a role in the sensitivity of cancer patients to radiotherapy PMID: 22199273
  26. Overexpression of REGIV mRNA is assessed with peritoneal recurrence in gastric adenocarcinoma. PMID: 21780125
  27. REG4 may be a prognostic indicator and a better serum marker than carcinoembryonic antigen and carbohydrate antigen 19-9 for early diagnosis of gastric cancer. PMID: 21419474
  28. GLI1 promotes RegIV transcription by binding to the RegIV gene promoter in pancreatic cancer. PMID: 21494603
  29. The solution structure of hRegIV-P91S was determined, showing that it adopts a typical fold of C-type lectin. Based on the chemical shift perturbations of amide resonances, two calcium-independent mannan-binding sites were proposed PMID: 20692269
  30. REG4 may play an important role in the development and progression of colorectal cancer, as well as in intestinal morphogenesis and epithelium restitution PMID: 20126989
  31. RegIV is expressed in the gastrointestinal tract and in digestive tract neuroendocrine tumor PMID: 20349522
  32. REG IV overexpression may be an early event in colorectal carcinoma carcinogenesis. PMID: 20183800
  33. RegIV enhances LoVo cell migration and invasion, and its CRD domain is critical for these effects. PMID: 20417867
  34. REG4 is expressed in pancreatic cancer, and serum levels of REG4 offer a useful indicator for distinguishing between patients with pancreatic cancer and healthy subjects PMID: 19789838
  35. Reg IV as an important modulator of gastrointestinal cell susceptibility to irradiation; hence, it is a potential target for adjunctive treatments for human colorectal cancer and other gastrointestinal malignancies. PMID: 19900450
  36. reg4 is amplified in the early stages of pancreatic cancer development PMID: 19834624
  37. Data demonstrated in vitro and in vivo that REG4 protein overexpression was associated with an unfavorable response to preoperative chemoradiotherapy. PMID: 19546835
  38. Local Reg IV expression may be influenced by the growth factors basic fibroblast growth factor and somatotropin and dtheri receptors PMID: 19924642
  39. Results suggest that RELP might be involved in inflammatory and metaplastic responses of the gastrointestinal epithelium. PMID: 12819006
  40. overexpression of Reg IV may be an early event in colorectal carcinogenesis. PMID: 14550954
  41. Increased expression of Reg IV is associated wirh hormone refractory metastatic prostate cancer PMID: 15788672
  42. RELP serves as a marker for appendiceal mucinous cystadenomas and pseudomyxoma peritonei and may contribute to the pathogenesis of these disorders. PMID: 16323007
  43. Reg IV is a potent activator of the EGF receptor/Akt/AP-1 signaling pathway in colorectal carcinoma PMID: 16401477
  44. Overexpression of REG4 is associated with pancreatic cancer PMID: 16918991
  45. serum Reg IV concentration may predict metastatic recurrence of colorectal cancer in the liver.Reg IV protein expression induced by growth factors may function as a growth-promoting and/or an antiapoptotic factor in the peritumoral mucosa of CRC. PMID: 18187959
  46. RegIV expression was markedly higher in gastric cancer patients with peritoneal metastases compared to those without; level of RegIV mRNA in gastric cancer patients was related to the extent of wall penetration PMID: 18505053
  47. Reg IV staining can aid in diagnosis of gastrointestinal signet ring cell carcinoma. PMID: 18580680
  48. These results suggest that Reg IV expression is an independent prognostic indicator of relapse after radical prostatectomy. PMID: 18754868
  49. Reg IV might accelerate cell growth and disease progression of adenoid cystic carcinomas . PMID: 19076683
  50. among major urologic cancers, Reg IV is expressed frequently in prostate cancer, and that serum Reg IV represents a novel biomarker for prostate cancer PMID: 19082448

Show More

Hide All

Subcellular Location
Secreted.
Tissue Specificity
Highly expressed in the gastrointestinal tract including the duodenum, jejunum, ileum, ileocecum, appendix, descending colon, pancreas and small intestine. Weakly expressed in normal colon and stomach. Strongly expressed in most colorectal tumors than in
Database Links

HGNC: 22977

OMIM: 609846

KEGG: hsa:83998

STRING: 9606.ENSP00000256585

UniGene: Hs.660883

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*